• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry.

作者信息

Psaty Bruce M, Rennie Drummond

出版信息

JAMA. 2006 Jun 21;295(23):2787-90. doi: 10.1001/jama.295.23.2787.

DOI:10.1001/jama.295.23.2787
PMID:16788134
Abstract
摘要

相似文献

1
Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry.临床试验研究者及其处方模式：医师研究者与制药行业关系的另一个层面。
JAMA. 2006 Jun 21;295(23):2787-90. doi: 10.1001/jama.295.23.2787.
2
How conducting a clinical trial affects physicians' guideline adherence and drug preferences.开展临床试验如何影响医生对指南的遵循及药物偏好。
JAMA. 2006 Jun 21;295(23):2759-64. doi: 10.1001/jama.295.23.2759.
3
Characteristics of primary health care units with focus on drug information from the pharmaceutical industry and adherence to prescribing objectives: a cross-sectional study.关注来自制药行业的药品信息及遵循处方目标的基层医疗单位特征：一项横断面研究
BMC Clin Pharmacol. 2010 Feb 15;10:4. doi: 10.1186/1472-6904-10-4.
4
Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?3期临床试验中的临床资助支付方式会影响后续临床研究者的处方行为吗？
Dis Manag. 2004 Spring;7(1):77-87. doi: 10.1089/109350704322919014.
5
Are we too fixated on clinical trial data? The case for using embedded case histories to influence prescribing.
Health Mark Q. 2005;23(1):3-19. doi: 10.1300/j026v23n01_02.
6
Pharmaceutical marketing research and the prescribing physician.药品营销研究与开处方的医生。
Ann Intern Med. 2007 May 15;146(10):742-8. doi: 10.7326/0003-4819-146-10-200705150-00008.
7
NNTs and NNHs: essential for rational prescribing.需治人数和需害人数：合理用药的关键要素。
Br J Gen Pract. 2017 Mar;67(656):132. doi: 10.3399/bjgp17X689785X.
8
Direct-to-consumer advertising and physician prescribing.直接面向消费者的广告与医生开处方
JAMA. 2005 Aug 10;294(6):678; author reply 678-9. doi: 10.1001/jama.294.6.678-a.
9
Physician education and prescribing costs.
Pharmacoeconomics. 1993 Aug;4(2):77-84. doi: 10.2165/00019053-199304020-00002.
10
Building legitimacy by criticising the pharmaceutical industry: a qualitative study among prescribers and local opinion leaders.通过批评制药行业来建立合法性：一项针对开药者和地方意见领袖的定性研究。
Swiss Med Wkly. 2015 Dec 10;145:w14240. doi: 10.4414/smw.2015.14240. eCollection 2015.

引用本文的文献

1
Off-Label Use vs Off-Label Marketing: Part 2: Off-Label Marketing-Consequences for Patients, Clinicians, and Researchers.药品未按批准用途使用与药品未按批准用途营销：第2部分：药品未按批准用途营销对患者、临床医生和研究人员的影响
JACC Basic Transl Sci. 2023 Mar 27;8(3):359-370. doi: 10.1016/j.jacbts.2022.12.012. eCollection 2023 Mar.
2
Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs.欧盟与美国在药品监管事务上的差异影响全球患者安全标准和公众健康意识：以地拉罗司及其他铁螯合剂药物为例
Medicines (Basel). 2021 Jul 7;8(7):36. doi: 10.3390/medicines8070036.
3
Pitfalls and Safeguards in Industry-Funded Research.
行业资助研究中的陷阱与保障措施。
Ochsner J. 2020 Spring;20(1):104-110. doi: 10.31486/toj.19.0093.
4
Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.阿尔茨海默病药物治疗的证据强度和研究冗余性研究：累积荟萃分析和试验序贯分析。
Eur J Clin Pharmacol. 2019 Dec;75(12):1659-1667. doi: 10.1007/s00228-019-02742-w. Epub 2019 Aug 21.
5
Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.行业资助的上市后研究对药物安全性的贡献：提交给监管机构的通报调查
BMJ. 2017 Feb 7;356:j337. doi: 10.1136/bmj.j337.
6
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016.
7
New developments and controversies in iron metabolism and iron chelation therapy.铁代谢与铁螯合疗法的新进展及争议
World J Methodol. 2016 Mar 26;6(1):1-19. doi: 10.5662/wjm.v6.i1.1.
8
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.
9
Research ethics. Rethinking research ethics: the case of postmarketing trials.研究伦理。反思研究伦理：上市后试验案例。
Science. 2012 May 4;336(6081):544-5. doi: 10.1126/science.1216086.
10
Promoting transparency in pharmaceutical industry-sponsored research.促进制药行业赞助研究的透明度。
Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.